Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Sarepta Therapeutics Inc (NASDAQ:SRPT), Johnson & Johnson(NYSE:JNJ) ,Dynavax Technologies Corporation(NASDAQ:DVAX), Zoetis Inc(NYSE:ZTS)
Sarepta Therapeutics Inc (NASDAQ:SRPT) managed to keep its gain at 18.02% on below-normal volume of 15.74 million shares. The stock settled at $43.30 after floating in a range of $13.99 to $46.16. Its latest price was $43.30, reaching market capitalization of $1.45 billion. Its 52-week range has been $13.99 to $47.35. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases.
What was the Moving Force behind SRPT On Bullish Run? Read This Research Report on SRPT
Johnson & Johnson(NYSE:JNJ) traded down on a volume of 14.72 million, higher than its standard daily volume. Shares have dropped -0.43% to $89.68. Over the last twelve months, the stock has added 29.86% and faced a worst price of $89.68. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
Has JNJ Found The Bottom And Ready To Gain Momentum? Find Out Here
Dynavax Technologies Corporation(NASDAQ:DVAX) settled +6.78% higher at $1.26 on above-normal volume of 21.46 million shares during the last trading day. The stock has its 12-month high at $5.10 and 52-week low price was $0.98. It traded in a range of $1.15 to $1.46 during the last trading day. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
For How Long DVAX Gloss will Attract Investors? Find out via this report
Zoetis Inc(NYSE:ZTS) saw its price fall on above-normal volume, as 11.40 million shares changed hands when compared with its average daily volume of 4.33million shares. The stock was down -0.98% to $.0280. It has fallen/gained over the last 12 months, increasing 3.81% and marked new low $28.81. Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States, Europe, Africa, the Middle East, Canada, Latin America, and the Asia/Pacific.
Will ZTS Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)